Targeting adaptive EGFR feedback enhances the therapeutic efficacy of RMC-6236 in cholangiocarcinoma
Shiori Yamazaki, Nao Hondo, Koya Yasukawa, Masato Kitazawa, Satoshi Nakamura, Yuta Yamamoto, Satoru Miyazaki, Hirokazu Tanaka, Masatsugu Kuroiwa, Naoki Ishizaka, Tadaaki Shimizu, Akira Shimizu, Yuji Soejima · 2026
Read Targeting adaptive EGFR feedback enhances the therapeutic efficacy of RMC-6236 in cholangiocarcinoma by Shiori Yamazaki, Nao Hondo, Koya Yasukawa, Masato Kitazawa, Satoshi Nakamura, Yuta Yamamoto, Satoru Miyazaki, Hirokazu Tanaka, Masatsugu Kuroiwa, Naoki Ishizaka, Tadaaki Shimizu, Akira Shimizu, Yuji Soejima (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13633637.txt.
Description
Shiori Yamazaki and co-authors hunt a resistance path in bile duct cancer in a 2026 study. About a fifth of these cancers carry a gene change that a new drug can block, and early trials of the drug look hopeful.
Dish and mouse tests show the drug halts growth of changed cells at tiny doses and quiets a key growth signal. Yet the same drug lifts a surface switch that can restart growth, a feedback loop. Adding a drug that blocks that switch, or a classic cancer drug, deepened the effect in both dishes and mice. The team frame the feedback as a weak spot worth hitting.
Catalog record
| CREATOR | Shiori Yamazaki, Nao Hondo, Koya Yasukawa, Masato Kitazawa, Satoshi Nakamura, Yuta Yamamoto, Satoru Miyazaki, Hirokazu Tanaka, Masatsugu Kuroiwa, Naoki Ishizaka, Tadaaki Shimizu, Akira Shimizu, Yuji Soejima |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 75 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |